Bone Marrow Stromal Cells Combined with Oxiracetam Influences the Expression of B-cell Lymphoma 2 in Rats with Ischemic Stroke
This study aimed to investigate the combination effects of bone marrow stromal cells (BMSCs) and oxiracetam for ischemic stroke. Forty Sprague Dawley female rats (220 ± 20 g) were subjected to a 2-hour ischemic middle cerebral artery occlusion (MCAO)–24 hours reperfusion model. The rats were randoml...
Gespeichert in:
| Veröffentlicht in: | Journal of stroke and cerebrovascular diseases 2014-11, Vol.23 (10), p.2591-2597 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2597 |
|---|---|
| container_issue | 10 |
| container_start_page | 2591 |
| container_title | Journal of stroke and cerebrovascular diseases |
| container_volume | 23 |
| creator | Wang, Chunyan, MM Li, Fangqin, MM Guan, Yu, MM Zhu, Lei, MM Fei, Yiping, MD Zhang, Jiadong, MM Pan, Yujun, MD |
| description | This study aimed to investigate the combination effects of bone marrow stromal cells (BMSCs) and oxiracetam for ischemic stroke. Forty Sprague Dawley female rats (220 ± 20 g) were subjected to a 2-hour ischemic middle cerebral artery occlusion (MCAO)–24 hours reperfusion model. The rats were randomly divided into 4 groups. Rats from BMSCs group, oxiracetam group, and BMSCs + oxiracetam group accepted injection of BMSCs (3 × 106 cells), oxiracetam (800 mg/kg), and BMSCs + oxiracetam, respectively. Rats from control group did not receive any interventions after ischemia reperfusion. The neurologic function was examined by modified neurological severity scores (mNSS). B-cell lymphoma 2 (Bcl-2) expression and apoptosis were detected by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The mNSS was decreased in all treatment groups and that in BMSCs + oxiracetam group was lower than BMSCs group and oxiracetam group ( P |
| doi_str_mv | 10.1016/j.jstrokecerebrovasdis.2014.05.035 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1634274572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1052305714002821</els_id><sourcerecordid>1634274572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-76111760871c806400da9c39ffa2e45ce9c898cd8ec9cc7f0ba88507944368f93</originalsourceid><addsrcrecordid>eNqVkkFv1DAQhSMEoqXwF5CPCCnBduLEuSCxq5autKgShbPlnUy03k3ixZO03Qu_HadbOCAunOzD8_c8702SvBc8E1yUH3bZjsbg9wgYcBP8naXGUSa5KDKuMp6rZ8m5ULlMtRLiebxzJdOcq-oseUW041wIpdXL5EwqWVZKV-fJz4UfkH2xIfh7dhvpve3YEruO2NL3Gzdgw-7duGU3Dy5YwNH2bDW03YQDILFxi-zy4RCQyPmB-ZYtUoiv2frYH7YRxiRzA_tqRzphVgRb7B08eu3xdfKitR3hm6fzIvl-dflteZ2ubz6vlp_WKRSqHtOqFEJUJdeVAM3LgvPG1pDXbWslFgqwBl1raDRCDVC1fGO1VryqiyIvdVvnF8m7E_cQ_I8JaTS9o_mjdkA_kRFlXsiqUJWM0sVJCsETBWzNIbjehqMR3Mw9mJ35Vw9m7sFwZWIPEfL2yW_a9Nj8QfwOPgrWJwHGqe8cBkPg5kwbFxBG03j3f34f_8JB5wYHttvjEWnnpzDEfI0wJA03t_NmzIshYpRSS5H_AhkVvTo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1634274572</pqid></control><display><type>article</type><title>Bone Marrow Stromal Cells Combined with Oxiracetam Influences the Expression of B-cell Lymphoma 2 in Rats with Ischemic Stroke</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Wang, Chunyan, MM ; Li, Fangqin, MM ; Guan, Yu, MM ; Zhu, Lei, MM ; Fei, Yiping, MD ; Zhang, Jiadong, MM ; Pan, Yujun, MD</creator><creatorcontrib>Wang, Chunyan, MM ; Li, Fangqin, MM ; Guan, Yu, MM ; Zhu, Lei, MM ; Fei, Yiping, MD ; Zhang, Jiadong, MM ; Pan, Yujun, MD</creatorcontrib><description>This study aimed to investigate the combination effects of bone marrow stromal cells (BMSCs) and oxiracetam for ischemic stroke. Forty Sprague Dawley female rats (220 ± 20 g) were subjected to a 2-hour ischemic middle cerebral artery occlusion (MCAO)–24 hours reperfusion model. The rats were randomly divided into 4 groups. Rats from BMSCs group, oxiracetam group, and BMSCs + oxiracetam group accepted injection of BMSCs (3 × 106 cells), oxiracetam (800 mg/kg), and BMSCs + oxiracetam, respectively. Rats from control group did not receive any interventions after ischemia reperfusion. The neurologic function was examined by modified neurological severity scores (mNSS). B-cell lymphoma 2 (Bcl-2) expression and apoptosis were detected by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The mNSS was decreased in all treatment groups and that in BMSCs + oxiracetam group was lower than BMSCs group and oxiracetam group ( P < .05). The expression of Bcl-2 was unregulated in all treatment groups ( P < .05), and similarly, the expression of Bcl-2 in BMSCs + oxiracetam group was higher than BMSCs group and oxiracetam group ( P < .05). Control group displayed more TUNEL-positive cells than the treatment groups, and BMSCs + oxiracetam group displayed less apoptotic cells than BMSCs group or oxiracetam group ( P < .05). Transplantation of BMSCs can promote the recovery of neurologic function in MCAO rats, and the effect of BMSCs combined with oxiracetam was better than the either one. Upregulation of Bcl-2 resulting in a decrease of apoptosis may be one of the mechanisms of BMSCs treatment for cerebral ischemic stroke.</description><identifier>ISSN: 1052-3057</identifier><identifier>EISSN: 1532-8511</identifier><identifier>DOI: 10.1016/j.jstrokecerebrovasdis.2014.05.035</identifier><identifier>PMID: 25267587</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Bcl-2 ; BMSCs ; Bone Marrow Cells - cytology ; Bone Marrow Cells - metabolism ; Bone Marrow Transplantation - methods ; Brain Ischemia - metabolism ; Brain Ischemia - therapy ; Cardiovascular ; Combined Modality Therapy - methods ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Female ; Ischemic stroke ; Mesenchymal Stromal Cells - cytology ; Mesenchymal Stromal Cells - metabolism ; Neurology ; Nootropic Agents - pharmacology ; oxiracetam ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; Pyrrolidines - administration & dosage ; Pyrrolidines - pharmacology ; Rats ; Rats, Sprague-Dawley ; Stroke - metabolism ; Stroke - therapy ; Treatment Outcome ; Up-Regulation - drug effects</subject><ispartof>Journal of stroke and cerebrovascular diseases, 2014-11, Vol.23 (10), p.2591-2597</ispartof><rights>National Stroke Association</rights><rights>2014 National Stroke Association</rights><rights>Copyright © 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-76111760871c806400da9c39ffa2e45ce9c898cd8ec9cc7f0ba88507944368f93</citedby><cites>FETCH-LOGICAL-c459t-76111760871c806400da9c39ffa2e45ce9c898cd8ec9cc7f0ba88507944368f93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.05.035$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25267587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Chunyan, MM</creatorcontrib><creatorcontrib>Li, Fangqin, MM</creatorcontrib><creatorcontrib>Guan, Yu, MM</creatorcontrib><creatorcontrib>Zhu, Lei, MM</creatorcontrib><creatorcontrib>Fei, Yiping, MD</creatorcontrib><creatorcontrib>Zhang, Jiadong, MM</creatorcontrib><creatorcontrib>Pan, Yujun, MD</creatorcontrib><title>Bone Marrow Stromal Cells Combined with Oxiracetam Influences the Expression of B-cell Lymphoma 2 in Rats with Ischemic Stroke</title><title>Journal of stroke and cerebrovascular diseases</title><addtitle>J Stroke Cerebrovasc Dis</addtitle><description>This study aimed to investigate the combination effects of bone marrow stromal cells (BMSCs) and oxiracetam for ischemic stroke. Forty Sprague Dawley female rats (220 ± 20 g) were subjected to a 2-hour ischemic middle cerebral artery occlusion (MCAO)–24 hours reperfusion model. The rats were randomly divided into 4 groups. Rats from BMSCs group, oxiracetam group, and BMSCs + oxiracetam group accepted injection of BMSCs (3 × 106 cells), oxiracetam (800 mg/kg), and BMSCs + oxiracetam, respectively. Rats from control group did not receive any interventions after ischemia reperfusion. The neurologic function was examined by modified neurological severity scores (mNSS). B-cell lymphoma 2 (Bcl-2) expression and apoptosis were detected by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The mNSS was decreased in all treatment groups and that in BMSCs + oxiracetam group was lower than BMSCs group and oxiracetam group ( P < .05). The expression of Bcl-2 was unregulated in all treatment groups ( P < .05), and similarly, the expression of Bcl-2 in BMSCs + oxiracetam group was higher than BMSCs group and oxiracetam group ( P < .05). Control group displayed more TUNEL-positive cells than the treatment groups, and BMSCs + oxiracetam group displayed less apoptotic cells than BMSCs group or oxiracetam group ( P < .05). Transplantation of BMSCs can promote the recovery of neurologic function in MCAO rats, and the effect of BMSCs combined with oxiracetam was better than the either one. Upregulation of Bcl-2 resulting in a decrease of apoptosis may be one of the mechanisms of BMSCs treatment for cerebral ischemic stroke.</description><subject>Animals</subject><subject>Bcl-2</subject><subject>BMSCs</subject><subject>Bone Marrow Cells - cytology</subject><subject>Bone Marrow Cells - metabolism</subject><subject>Bone Marrow Transplantation - methods</subject><subject>Brain Ischemia - metabolism</subject><subject>Brain Ischemia - therapy</subject><subject>Cardiovascular</subject><subject>Combined Modality Therapy - methods</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Ischemic stroke</subject><subject>Mesenchymal Stromal Cells - cytology</subject><subject>Mesenchymal Stromal Cells - metabolism</subject><subject>Neurology</subject><subject>Nootropic Agents - pharmacology</subject><subject>oxiracetam</subject><subject>Proto-Oncogene Proteins c-bcl-2 - metabolism</subject><subject>Pyrrolidines - administration & dosage</subject><subject>Pyrrolidines - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Stroke - metabolism</subject><subject>Stroke - therapy</subject><subject>Treatment Outcome</subject><subject>Up-Regulation - drug effects</subject><issn>1052-3057</issn><issn>1532-8511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkkFv1DAQhSMEoqXwF5CPCCnBduLEuSCxq5autKgShbPlnUy03k3ixZO03Qu_HadbOCAunOzD8_c8702SvBc8E1yUH3bZjsbg9wgYcBP8naXGUSa5KDKuMp6rZ8m5ULlMtRLiebxzJdOcq-oseUW041wIpdXL5EwqWVZKV-fJz4UfkH2xIfh7dhvpve3YEruO2NL3Gzdgw-7duGU3Dy5YwNH2bDW03YQDILFxi-zy4RCQyPmB-ZYtUoiv2frYH7YRxiRzA_tqRzphVgRb7B08eu3xdfKitR3hm6fzIvl-dflteZ2ubz6vlp_WKRSqHtOqFEJUJdeVAM3LgvPG1pDXbWslFgqwBl1raDRCDVC1fGO1VryqiyIvdVvnF8m7E_cQ_I8JaTS9o_mjdkA_kRFlXsiqUJWM0sVJCsETBWzNIbjehqMR3Mw9mJ35Vw9m7sFwZWIPEfL2yW_a9Nj8QfwOPgrWJwHGqe8cBkPg5kwbFxBG03j3f34f_8JB5wYHttvjEWnnpzDEfI0wJA03t_NmzIshYpRSS5H_AhkVvTo</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Wang, Chunyan, MM</creator><creator>Li, Fangqin, MM</creator><creator>Guan, Yu, MM</creator><creator>Zhu, Lei, MM</creator><creator>Fei, Yiping, MD</creator><creator>Zhang, Jiadong, MM</creator><creator>Pan, Yujun, MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141101</creationdate><title>Bone Marrow Stromal Cells Combined with Oxiracetam Influences the Expression of B-cell Lymphoma 2 in Rats with Ischemic Stroke</title><author>Wang, Chunyan, MM ; Li, Fangqin, MM ; Guan, Yu, MM ; Zhu, Lei, MM ; Fei, Yiping, MD ; Zhang, Jiadong, MM ; Pan, Yujun, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-76111760871c806400da9c39ffa2e45ce9c898cd8ec9cc7f0ba88507944368f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Bcl-2</topic><topic>BMSCs</topic><topic>Bone Marrow Cells - cytology</topic><topic>Bone Marrow Cells - metabolism</topic><topic>Bone Marrow Transplantation - methods</topic><topic>Brain Ischemia - metabolism</topic><topic>Brain Ischemia - therapy</topic><topic>Cardiovascular</topic><topic>Combined Modality Therapy - methods</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Ischemic stroke</topic><topic>Mesenchymal Stromal Cells - cytology</topic><topic>Mesenchymal Stromal Cells - metabolism</topic><topic>Neurology</topic><topic>Nootropic Agents - pharmacology</topic><topic>oxiracetam</topic><topic>Proto-Oncogene Proteins c-bcl-2 - metabolism</topic><topic>Pyrrolidines - administration & dosage</topic><topic>Pyrrolidines - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Stroke - metabolism</topic><topic>Stroke - therapy</topic><topic>Treatment Outcome</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Chunyan, MM</creatorcontrib><creatorcontrib>Li, Fangqin, MM</creatorcontrib><creatorcontrib>Guan, Yu, MM</creatorcontrib><creatorcontrib>Zhu, Lei, MM</creatorcontrib><creatorcontrib>Fei, Yiping, MD</creatorcontrib><creatorcontrib>Zhang, Jiadong, MM</creatorcontrib><creatorcontrib>Pan, Yujun, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of stroke and cerebrovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Chunyan, MM</au><au>Li, Fangqin, MM</au><au>Guan, Yu, MM</au><au>Zhu, Lei, MM</au><au>Fei, Yiping, MD</au><au>Zhang, Jiadong, MM</au><au>Pan, Yujun, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone Marrow Stromal Cells Combined with Oxiracetam Influences the Expression of B-cell Lymphoma 2 in Rats with Ischemic Stroke</atitle><jtitle>Journal of stroke and cerebrovascular diseases</jtitle><addtitle>J Stroke Cerebrovasc Dis</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>23</volume><issue>10</issue><spage>2591</spage><epage>2597</epage><pages>2591-2597</pages><issn>1052-3057</issn><eissn>1532-8511</eissn><abstract>This study aimed to investigate the combination effects of bone marrow stromal cells (BMSCs) and oxiracetam for ischemic stroke. Forty Sprague Dawley female rats (220 ± 20 g) were subjected to a 2-hour ischemic middle cerebral artery occlusion (MCAO)–24 hours reperfusion model. The rats were randomly divided into 4 groups. Rats from BMSCs group, oxiracetam group, and BMSCs + oxiracetam group accepted injection of BMSCs (3 × 106 cells), oxiracetam (800 mg/kg), and BMSCs + oxiracetam, respectively. Rats from control group did not receive any interventions after ischemia reperfusion. The neurologic function was examined by modified neurological severity scores (mNSS). B-cell lymphoma 2 (Bcl-2) expression and apoptosis were detected by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. The mNSS was decreased in all treatment groups and that in BMSCs + oxiracetam group was lower than BMSCs group and oxiracetam group ( P < .05). The expression of Bcl-2 was unregulated in all treatment groups ( P < .05), and similarly, the expression of Bcl-2 in BMSCs + oxiracetam group was higher than BMSCs group and oxiracetam group ( P < .05). Control group displayed more TUNEL-positive cells than the treatment groups, and BMSCs + oxiracetam group displayed less apoptotic cells than BMSCs group or oxiracetam group ( P < .05). Transplantation of BMSCs can promote the recovery of neurologic function in MCAO rats, and the effect of BMSCs combined with oxiracetam was better than the either one. Upregulation of Bcl-2 resulting in a decrease of apoptosis may be one of the mechanisms of BMSCs treatment for cerebral ischemic stroke.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25267587</pmid><doi>10.1016/j.jstrokecerebrovasdis.2014.05.035</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1052-3057 |
| ispartof | Journal of stroke and cerebrovascular diseases, 2014-11, Vol.23 (10), p.2591-2597 |
| issn | 1052-3057 1532-8511 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1634274572 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Animals Bcl-2 BMSCs Bone Marrow Cells - cytology Bone Marrow Cells - metabolism Bone Marrow Transplantation - methods Brain Ischemia - metabolism Brain Ischemia - therapy Cardiovascular Combined Modality Therapy - methods Disease Models, Animal Dose-Response Relationship, Drug Female Ischemic stroke Mesenchymal Stromal Cells - cytology Mesenchymal Stromal Cells - metabolism Neurology Nootropic Agents - pharmacology oxiracetam Proto-Oncogene Proteins c-bcl-2 - metabolism Pyrrolidines - administration & dosage Pyrrolidines - pharmacology Rats Rats, Sprague-Dawley Stroke - metabolism Stroke - therapy Treatment Outcome Up-Regulation - drug effects |
| title | Bone Marrow Stromal Cells Combined with Oxiracetam Influences the Expression of B-cell Lymphoma 2 in Rats with Ischemic Stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A00%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20Marrow%20Stromal%20Cells%20Combined%20with%20Oxiracetam%20Influences%20the%20Expression%20of%20B-cell%20Lymphoma%202%20in%20Rats%20with%20Ischemic%20Stroke&rft.jtitle=Journal%20of%20stroke%20and%20cerebrovascular%20diseases&rft.au=Wang,%20Chunyan,%20MM&rft.date=2014-11-01&rft.volume=23&rft.issue=10&rft.spage=2591&rft.epage=2597&rft.pages=2591-2597&rft.issn=1052-3057&rft.eissn=1532-8511&rft_id=info:doi/10.1016/j.jstrokecerebrovasdis.2014.05.035&rft_dat=%3Cproquest_cross%3E1634274572%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1634274572&rft_id=info:pmid/25267587&rft_els_id=1_s2_0_S1052305714002821&rfr_iscdi=true |